Please login to the form below

Not currently logged in
Email:
Password:

BIND Biosciences

This page shows the latest BIND Biosciences news and features for those working in and with pharma, biotech and healthcare.

Amgen signs $180m nanotechnology cancer deal

Amgen signs $180m nanotechnology cancer deal

Amgen signs $180m nanotechnology cancer deal. Will combine BIND Biosciences' tissue-targeting technology with a molecularly-targeted drug. ... Amgen has teamed up with nanotechnology specialist BIND Biosciences to develop a new version of one of its

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest from PMHub

  • Use of biomarkers in marketing

    Mark Assenti is a Senior Associate Consultant at Blue Latitude. Mark began his career in the biosciences field, studying genetics at Cardiff University.

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Redline Strategic

We are a healthcare consultancy, specialising in people and experiences. Using innovative research methods to capture the thoughts of real...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics